bioRxivCancer BiologyPreprint
3D vascularized microtumors unveil aberrant ccRCC vasculature and differential sensitivity to targeted treatments
Noémie Brassard-JolliveiD, Yoann AtlasiD, Camille LM Compere, Corinne Ardidie‐Robouant, Philippe MaillyiD, Morad El Bouchtaoui, Virginie Lelarge, Guillaume BlotiD, Nathalie JosseaumeiD, Stéphanie De Oliveira, Christophe HélaryiD, Christophe LebœufiD, Isabelle CremeriD, Mathilde SibonyiD, Guilhem BousquetiD, Stéphane GermainiD, Laurent MulleriD, Catherine MonnotiD
Abstract
Clear cell renal cell carcinoma (ccRCC) is largely driven by Von Hippel Lindau (VHL) protein deficiency, promoting epithelial-mesenchymal transition, invasion, and hypervascularization, mediated by vascular endothelial growth factor (VEGF) signaling resulting in a structurally abnormal capillary network, which remains insufficiently defined. Previous studies correlating patient outcome with microvascular density yielded diverse results, underscoring the limitations of conventional parameters to fully capture vascular complexity. While VEGF-targeted anti-angiogenic first-line therapies such as sunitinib prolong progression-free survival in metastatic ccRCC, their efficacy is hampered by resistance mechanisms. This study aims to elucidate the three-dimensional architecture of ccRCC-specific vasculature in the tumor microenvironment, and its response to targeted therapies. Analysis of human ccRCC samples identified two distinct vascular structures, markedly differing from tumor capillaries, termed ponds and sheets, which were further characterized in patient-derived xenografts using advanced 3D microscopy on optically cleared samples. Ponds are large, dilated, irregular structures with wide cavity, whereas sheets are thin, elongated, and collapsed structures. To further dissect endothelial network morphogenesis, we developed an innovative in vitro 3D vascularized microtumor model, faithfully recapitulating the aberrant pond architecture. Dynamic live imaging unraveled the temporal relationship between tumor invasion and pond morphogenesis. Additionally, drug sensitivity assays demonstrated that ponds exhibit lower responsiveness to sunitinib compared to tumor capillaries. Altogether, our 3D model not only captures a specific architecture of ccRCC vascular network but also provides mechanistic insight into its development and therapeutic sensitivity. This model offers a promising avenue for personalized treatment assessment and for identification of novel therapeutic strategies. Statement of significanceA co-culture-engineered model integrating tumor spheroid invasion and capillary morphogenesis recapitulates the ccRCC endothelial structures and their response to treatments.
- organism: human
- assay: imaging
- research focus: cell type annotation
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Vascularized tumor on a microfluidic chip to study mechanisms promoting tumor neovascularization and vascular targeted therapies
M. Skubal, B. E. Mc Larney, … J. Grimm·bioRxiv·Aug 7, 2023
- Single-cell transcriptional profiling of clear cell renal cell carcinoma reveals an invasive tumor vasculature phenotype
J. Zvirblyte, J. Nainys, … L. Mazutis·bioRxiv·Aug 9, 2023
- An Innervated and Vascularized HNSCC-on-a-Chip Model Built on Defined and Tunable Engineered Extracellular Matrices
Alessia Maria Pignataro, Cornelia Christina Schwarz, … Pierfrancesco Pagella·Proceedings of the National Academy of SciencesPeer-reviewed·Oct 27, 2026
- Modeling Hepatocellular Carcinoma and its microenvironment on a chip
Orsola Mocellin, Stéphane Treillard, … Karla C. S. Queiroz·bioRxiv·Jul 10, 2025
- An In Vitro Vascularized Micro-Tumor Model of Human Colorectal Cancer Recapitulates In Vivo Drug Responses
S. J. Hachey, S. Movsesyan, … C. C. Hughes·bioRxiv·Mar 3, 2020
- Targeting TR4-induced RCC cells-derived exosomally initiated signaling increases Sunitinib efficacy